Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six MonthsPRNewsWire • Wednesday
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual MeetingPRNewsWire • 11/14/24
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024PRNewsWire • 11/13/24
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisPRNewsWire • 11/12/24
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 MillionPRNewsWire • 10/31/24
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024PRNewsWire • 10/28/24
Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee OsteoarthritisPRNewsWire • 10/15/24
Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024PRNewsWire • 10/10/24
Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal DiseasesPRNewsWire • 09/19/24
Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisPRNewsWire • 09/11/24
Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment ConferencePRNewsWire • 09/04/24
Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and ExpoPRNewsWire • 07/08/24
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024PRNewsWire • 07/03/24
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of ShareholdersPRNewsWire • 06/06/24
Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024PRNewsWire • 06/05/24
Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisPRNewsWire • 05/23/24
Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024PRNewsWire • 05/22/24
Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisPRNewsWire • 05/21/24
Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024PRNewsWire • 05/14/24
Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdatePRNewsWire • 05/08/24